FACT: Summary for Facet Biotech Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 5:48am EST - Canadian Markets open in 3 hours and 42 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Facet Biotech Corporation (FACT)

On Feb 9: 15.77 USD 0.00 (0.00%)

MORE ON FACT

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Facet Biotech Corporation (NGM:FACT) Delayed quote data

Last Trade:	15.77 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	15.77
Open:	N/A
Bid:	N/A
Ask:	16.60 x 300
1y Target Est:	24.00

Day's Range:	N/A - N/A
52wk Range:	5.86 - 18.35
Volume:	0
Avg Vol (3m):	211,032
Market Cap:	395.31M
P/E (ttm):	N/A
EPS (ttm):	-6.73
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y

Add FACT to Portfolio

Download Data

HEADLINES

•	FACET BIOTECH CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
	EDGAR Online (Tue 8:16am)

•	Cash Rich, No Debt Stocks
	at Investopedia (Mon, Feb 8)

•	[$$] 13D Filings
	at Barrons.com (Sat, Feb 6)

•	President Sergey Brin Sells $44.3M Worth of Google
	TheStreet.com (Fri, Feb 5)

•	FACET BIOTECH CORP Files SEC form 8-K, Termination of a Material Definitive Agreement
	EDGAR Online (Wed, Feb 3)

•	Facet Biotech to Present at 12th Annual Bio CEO & Investor Conference
	Marketwire (Tue, Feb 2)

•	President James Truchard Sells $7.7M National Instruments
	TheStreet.com (Mon, Feb 1)

•	FACET BIOTECH CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
	EDGAR Online (Tue, Jan 26)

•	Those Are Fighting Words
	at Motley Fool (Wed, Jan 20)

•	Facet Biotech receiving $15 million from partner
	AP (Mon, Jan 11)

More Headlines for FACT...

ANALYST

EPS Est (next year) (Dec-09) :	-6.01
EPS Est (in 2 years) (Dec-10) :	-3.79
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha ...

Full Company Profile

Add to Portfolio

Email to a Friend

•